Precipio Inc Stock Price, News & Analysis

Precipio (NASDAQ: PRPO) reported a 45% increase in revenues for 2021, totaling $8.9 million, driven primarily by pathology diagnostic testing. Q4 revenues reached $2.4 million, a 25% rise from the previous year. The HemeScreen product line is expected to contribute to further growth, with annualized contracts exceeding $1.6 million. Despite challenges from COVID-19, the company is optimistic about 2022, predicting significant revenue growth across its diagnostics segment, aiming to reduce cash burn and improve financial stability.

Precipio, Inc. (NASDAQ: PRPO) has announced that its HemeScreen RUO assay has received approval from the New York State Department of Health (NY DOH). This allows physician-owned laboratories (POLs) in New York to apply to run HemeScreen as a laboratory-developed test (LDT). The first customer, New York Cancer & Blood Specialists, estimates a potential for seven-figure revenues from HemeScreen, along with a Florida-based customer also utilizing the assay. This marks a significant milestone for Precipio, enhancing its market presence and potentially reducing cash burn.

Precipio, a specialty cancer diagnostics company (NASDAQ: PRPO), will host its Q3-2021 update conference call on November 15, 2021, at 5:00 PM ET. The call aims to provide updates on the company’s core businesses and can be accessed by calling 844-695-5519 or through pre-registration at their website. Precipio collaborates with renowned institutions like Yale and Dana-Farber to improve diagnostic accuracy in cancer care. Replay access will be available 24 hours post-call via their Investors page.

Precipio, Inc. (NASDAQ: PRPO) has signed a multi-year agreement with American Oncology Network (AON) to implement HemeScreen technology in AON's laboratory in Fort Myers, Florida. This partnership allows AON, the largest Physician Owned Laboratory, to reduce diagnostic turnaround times from 2-4 weeks to 1-4 days, significantly improving patient care. The deal is expected to generate seven-figure annual revenue for Precipio.

Both companies aim to enhance oncology diagnostics, with AON serving around 100,000 patients annually.

Precipio, Inc. (NASDAQ: PRPO) has rescheduled its Q2 2021 update call from August 23 to August 26 at 5:00 PM ET due to a scheduling conflict. Interested participants can access the call by calling 844-695-5519 or registering in advance for a direct dial-in number. The call will allow for pre-submitted questions via email. A replay will be available 24 hours post-call on Precipio's investors page.

Precipio focuses on enhancing diagnostic accuracy through collaborations with esteemed cancer research institutions.

Precipio, a specialty cancer diagnostics company, announced it will host its Q2-2021 update call on August 23, 2021, at 5:00 PM ET. The call will cover key topics concerning its core businesses. A prior communication incorrectly referenced 'year-end' instead of 'Q2-2021 Company Update.' Access to the call can be obtained by dialing 844-695-5519, or pre-registering online for a direct dial-in. Questions can be submitted in advance via email. The company aims to enhance diagnostic accuracy through collaborations with leading academic institutions.

Precipio, Inc. (NASDAQ: PRPO) is scheduled to host its Q2-2021 conference call on August 23, 2021, at 5:00 PM ET. The call will provide updates on the company's core business operations. Interested participants can join via phone or pre-register online for direct access. The call will include a question-and-answer session, and listeners can submit inquiries in advance. A replay of the call will be available on the company's website within 24 hours. Precipio specializes in cancer diagnostics, aiming to improve diagnostic accuracy and reduce misdiagnosis.

Precipio, Inc. (NASDAQ: PRPO) reported a substantial increase in preliminary unaudited revenues for Q2-2021, boasting a 65% year-over-year growth and a 29% increase compared to Q1-2021. This growth is attributed to the company's thriving Pathology services which saw a 60% YoY increase in case volume, and the expanding HemeScreen POL program. The latter has led to a recurring B2B revenue model with commitments from clients for up to four years, boosting operational efficiency and reducing cash burn. The company remains optimistic about continued revenue acceleration throughout the year.

Precipio, Inc. (NASDAQ: PRPO) has terminated its equity line financing with Lincoln Park Capital. The company states that this decision comes as a result of growing revenues, improved gross margins, and a strong cash position, eliminating the anticipated need for further capital raises in the near future. CEO Ilan Danieli expressed gratitude for Lincoln Park's support and noted that the company is now well-positioned for growth without relying on additional funding for at least the next 24 months.